IL28B genotype predicts response to chronic hepatitis C triple therapy with telaprevir or boceprevir in treatment naïve and treatment-experienced patients other than prior partial- and null-responders

Effectiveness of Telaprevir and Boceprevir Triple Therapy for Patients with Hepatitis C Virus Infection in a Large Integrated Care Setting

(2014) Jennifer C. Price et al.   DIGESTIVE DISEASES AND SCIENCES

Similar Effectiveness of Boceprevir and Telaprevir Treatment Regimens for Hepatitis C Virus Infection on the Basis of a Nationwide Study of Veterans

(2013) George N. Ioannou et al.   Clinical Gastroenterology and Hepatology

Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure

(2013) Stanislas Pol et al.   JOURNAL OF HEPATOLOGY

Factors That Predict Response of Patients With Hepatitis C Virus Infection to Boceprevir

(2012) Fred Poordad et al.   GASTROENTEROLOGY

Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection

(2012) Janett Fischer et al.   HEPATOLOGY

Does IL28B genotyping still have a role in the era of direct-acting antiviral therapy for chronic hepatitis C infection?

(2012) J. A. Holmes et al.   JOURNAL OF VIRAL HEPATITIS

Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care

(2012) Brian L Pearlman   LANCET INFECTIOUS DISEASES

IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C

(2011) P.-Y. Bochud et al.   JOURNAL OF HEPATOLOGY

IL28B genetic polymorphism testing in the era of direct acting antivirals therapy for chronic hepatitis C: ten years too late?

(2011) Donald M. Jensen et al.   LIVER INTERNATIONAL

Boceprevir for Untreated Chronic HCV Genotype 1 Infection

(2011) Fred Poordad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection

(2011) Bruce R. Bacon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Telaprevir for Retreatment of HCV Infection

(2011) Stefan Zeuzem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection

(2011) Ira M. Jacobson et al.   NEW ENGLAND JOURNAL OF MEDICINE

IL28B Genomic-Based Treatment Paradigms for Patients With Chronic Hepatitis C Infection: The Future of Personalized HCV Therapies

(2010) Paul J Clark et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Hepatic ISG Expression Is Associated With Genetic Variation in Interleukin 28B and the Outcome of IFN Therapy for Chronic Hepatitis C

(2010) Masao Honda et al.   GASTROENTEROLOGY

IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C

(2010) Thomas J. Urban et al.   HEPATOLOGY

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

(2009) Dongliang Ge et al.   NATURE

IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy

(2009) Vijayaprakash Suppiah et al.   NATURE GENETICS

Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C

(2009) Yasuhito Tanaka et al.   NATURE GENETICS